This Article is From Jun 10, 2020

Panacea Biotec To Partner With US-Based Refana Inc For COVID-19 Vaccine

The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges.

Panacea Biotec said it will collaborate with Refana Inc for COVID vaccine (Representational)

Bengaluru:

Biotech firm Panacea Biotec Ltd said on Wednesday it would partner with US-based Refana Inc to make a potential vaccine for COVID-19.

The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges.

Panacea's shares jumped 20% in morning trading on the National Stock Exchange after the news.